Disulfiram Tablets USP 250 mg, 100 tablet bottle, Rx only, Manufactured for TEVA Pharmaceuticals,...
FDA Drug Recall #D-578-2013 — Class III — March 19, 2013
Recall Summary
| Recall Number | D-578-2013 |
| Classification | Class III — Low risk |
| Date Initiated | March 19, 2013 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Teva Pharmaceuticals USA, Inc. |
| Location | Sellersville, PA |
| Product Type | Drugs |
| Quantity | 68,322 bottles |
Product Description
Disulfiram Tablets USP 250 mg, 100 tablet bottle, Rx only, Manufactured for TEVA Pharmaceuticals, USA, Sellersville, PA --- NDC 0093-5035-01
Reason for Recall
CGMP Deviation; cotton coil is missing in some packaged bottles
Distribution Pattern
Nationwide
Lot / Code Information
NDC 0093-5035-01, Lot numbers 14064211A, exp 3/2014; 14064311A, exp 3/2014; 14064411A, exp 3/2014; 14064511A, exp 3/2014; 14090312A, exp 4/2015; 14092512A, exp 4/2015; 14092712A, exp 4/2015; 14094612A, exp 4/2015; 14099412A, exp 4/2015; 14099612B, exp 4/2015; 14099712A, exp 5/2015; 14110111A, exp 5/2014; 14110211A, exp 5/2014; 14110311A, exp 5/2014; 14110411A, exp 5/2014 and 34090212A, exp 4/2015.
Other Recalls from Teva Pharmaceuticals USA, Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0518-2020 | Class II | Valganciclovir Hydrochloride for Oral Solution,... | Nov 4, 2019 |
| D-747-2014 | Class III | Fluconazole Oral Suspension, 10 mg/mL, 35 ml bo... | Nov 14, 2013 |
| D-1061-2014 | Class II | Valacyclovir Hydrochloride Tablets, 1 g, 30 cou... | Nov 8, 2013 |
| D-928-2013 | Class II | CARBOplatin Injection, 600 mg/60ml, MultiDose, ... | Aug 13, 2013 |
| D-924-2013 | Class II | Propranolol Hydrochloride Tablets, USP, 10 mg, ... | Aug 6, 2013 |
Frequently Asked Questions
cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.